Close Menu

NEW YORK (GenomeWeb) – As Foundation Medicine seeks to grow revenues from its clinical cancer profiling tests, the company has been hampered by a lack of coverage decisions from Medicare and no contracts with most commercial payors, resulting in payment delays and tens of thousands of unpaid tests.

The firm provides two clinical tests for cancer patients, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, each assaying several hundred genes for mutations that may impact treatment decisions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.